257 related articles for article (PubMed ID: 28320739)
1. A covalently bound inhibitor triggers EZH2 degradation through CHIP-mediated ubiquitination.
Wang X; Cao W; Zhang J; Yan M; Xu Q; Wu X; Wan L; Zhang Z; Zhang C; Qin X; Xiao M; Ye D; Liu Y; Han Z; Wang S; Mao L; Wei W; Chen W
EMBO J; 2017 May; 36(9):1243-1260. PubMed ID: 28320739
[TBL] [Abstract][Full Text] [Related]
2. Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2.
Liu Z; Hu X; Wang Q; Wu X; Zhang Q; Wei W; Su X; He H; Zhou S; Hu R; Ye T; Zhu Y; Wang N; Yu L
J Med Chem; 2021 Mar; 64(5):2829-2848. PubMed ID: 33606537
[TBL] [Abstract][Full Text] [Related]
3. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion.
Jin X; Yang C; Fan P; Xiao J; Zhang W; Zhan S; Liu T; Wang D; Wu H
J Biol Chem; 2017 Apr; 292(15):6269-6280. PubMed ID: 28242758
[TBL] [Abstract][Full Text] [Related]
4. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
5. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
[TBL] [Abstract][Full Text] [Related]
6. Targeting EZH2 as cancer therapy.
Hanaki S; Shimada M
J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
8. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
9. Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies.
Mei H; Wu H; Yang J; Zhou B; Wang A; Hu C; Qi S; Jiang Z; Zou F; Wang B; Liu F; Chen Y; Wang W; Liu J; Liu Q
Signal Transduct Target Ther; 2023 Jan; 8(1):18. PubMed ID: 36642705
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and antitumor activity of PLGA nanoparticles incorporating a discovered benzimidazole derivative as EZH2 inhibitor.
Elkot HA; Ragab I; Saleh NM; Amin MN; Al-Rashood ST; El-Messery SM; Hassan GS
Chem Biol Interact; 2021 Aug; 344():109530. PubMed ID: 34029540
[TBL] [Abstract][Full Text] [Related]
11. Naturally occurring anti-cancer agents targeting EZH2.
Shahabipour F; Caraglia M; Majeed M; Derosa G; Maffioli P; Sahebkar A
Cancer Lett; 2017 Aug; 400():325-335. PubMed ID: 28323035
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of EZH2-based PROTACs targeting PRC2 complex in lymphoma.
Xie H; Xu W; Liang J; Liu Y; Zhuo C; Zou X; Luo W; Xiao J; Lin Y; Chen L; Li H
Bioorg Chem; 2023 Nov; 140():106762. PubMed ID: 37572533
[TBL] [Abstract][Full Text] [Related]
13. Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay.
Murashima A; Shinjo K; Katsushima K; Onuki T; Kondoh Y; Osada H; Kagaya N; Shin-Ya K; Kimura H; Yoshida M; Murakami S; Kondo Y
J Biochem; 2019 Jul; 166(1):41-50. PubMed ID: 30690451
[TBL] [Abstract][Full Text] [Related]
14. NEAT1 regulates Th2 cell development by targeting STAT6 for degradation.
Huang S; Dong D; Zhang Y; Chen Z; Geng J; Zhao Y
Cell Cycle; 2019 Feb; 18(3):312-319. PubMed ID: 30654703
[TBL] [Abstract][Full Text] [Related]
15. PRAJA1 is a ubiquitin ligase for the polycomb repressive complex 2 proteins.
Zoabi M; Sadeh R; de Bie P; Marquez VE; Ciechanover A
Biochem Biophys Res Commun; 2011 May; 408(3):393-8. PubMed ID: 21513699
[TBL] [Abstract][Full Text] [Related]
16. Structural Basis of the Interaction Between Ubiquitin Specific Protease 7 and Enhancer of Zeste Homolog 2.
Gagarina V; Bojagora A; Lacdao IK; Luthra N; Pfoh R; Mohseni S; Chaharlangi D; Tan N; Saridakis V
J Mol Biol; 2020 Feb; 432(4):897-912. PubMed ID: 31866294
[TBL] [Abstract][Full Text] [Related]
17. CLDN14 is epigenetically silenced by EZH2-mediated H3K27ME3 and is a novel prognostic biomarker in hepatocellular carcinoma.
Li CP; Cai MY; Jiang LJ; Mai SJ; Chen JW; Wang FW; Liao YJ; Chen WH; Jin XH; Pei XQ; Guan XY; Zeng MS; Xie D
Carcinogenesis; 2016 Jun; 37(6):557-566. PubMed ID: 27207647
[TBL] [Abstract][Full Text] [Related]
18. Role of the EZH2 histone methyltransferase as a therapeutic target in cancer.
Italiano A
Pharmacol Ther; 2016 Sep; 165():26-31. PubMed ID: 27179746
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
20. Praja1 E3 ubiquitin ligase promotes skeletal myogenesis through degradation of EZH2 upon p38α activation.
Consalvi S; Brancaccio A; Dall'Agnese A; Puri PL; Palacios D
Nat Commun; 2017 Jan; 8():13956. PubMed ID: 28067271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
